Organon: FDA Extends Vtama Atopic-Dermatitis Review to March

WSJNov 5 08:00 ET

Express News | Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

ReutersOct 29 16:35 ET

Express News | Organon Completes Acquisition of Dermavant, Including Innovative Dermatologic Therapy, Vtama® (Tapinarof) Cream, 1%

ReutersOct 28 09:24 ET

Express News | Dermavant Presents Final Data From ADORING 3 LTE Study On VTAMA Cream, 1% At 2024 Fall Clinical Dermatology Conference; 51.9% Achieved Complete Disease Clearance And Remained Treatment-Free For ~80 Days; FDA PDUFA Action Date Expected Q4 2024

BenzingaOct 25 08:06 ET

Editas, Roivant's Genevant to Develop Gene Editing Therapies

Seeking AlphaOct 21 17:33 ET

Leerink Partners Maintains Roivant Sciences(ROIV.US) With Buy Rating

Moomoo NewsOct 21 08:31 ET · Ratings